Passage BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
Passage BIO, Inc. (PASG), a Delaware corporation, filed this Current Report on Form 8-K on August 12, 2025. The filing serves to announce financial results for the quarter ended June 30, 2025, and to disclose an update to the company's corporate presentation.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are referenced but not included in the provided text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the filing text. The report indicates that financial results for the quarter ended June 30, 2025, have been issued, but the specific variances are not disclosed in this document.
Guidance, Outlook, and Risks
The company updated its corporate presentation on August 12, 2025, which may contain updated guidance or outlook information. The filing explicitly states that the information in Item 2.02 and Item 7.01, including the attached exhibits, is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline milestones, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the attached exhibits.
- Confirm any changes in the company's emerging growth company status or accounting standard elections.